NICE Refusing to Reimburse Celegene Revlimid and Amgen Kyprolis as Second-line Treatment

NICE has published new draft guidelines turning down Celgene's Revlimid and Amgen's Kyprolis as a secondary treatment.

The committee turned down Revlimid early in treatment because they determined it would not be cost effective for the NHS.

Kyprolis was rejected due to uncertainties in the clinical trials and because the drug failed to meet the 24-month extension endpoint for end-of-life.